Health Catalyst Reports Third Quarter 2026 Results
Key Highlights
- ➤Total revenue $56.283 million, down 26% year over year
- ➤Adjusted EBITDA $779,000, down 94% year over year
- ➤Net income $40.496 million, largely driven by a $65.9 million Vitalware sale gain
- ➤2026 outlook reaffirmed: revenue $246 million-$249 million, Adjusted EBITDA $18 million-$18.5 million
Expert Statements
Simeon Kohl, President and Chief Executive Officer of Health Catalyst
“We delivered a third quarter above the high end of our revenue and Adjusted EBITDA guidance, and we are reaffirming our full-year outlook. Our immediate priority is to strengthen the foundation of the business, with a focus on retaining the clients we serve and developing a path to generating durable, profitable revenue.”
SALT LAKE CITY, Nov. 05, 2026 (GLOBE NEWSWIRE) -- Health Catalyst, Inc. (“Health Catalyst,” Nasdaq: HCAT), a healthcare intelligence company designed to accelerate measurable improvement for health systems, today reported financial results for the quarter ended September 30, 2026.
“We delivered a third quarter above the high end of our revenue and Adjusted EBITDA guidance, and we are reaffirming our full-year outlook,” said Simeon Kohl, President and Chief Executive Officer of Health Catalyst. “Our immediate priority is to strengthen the foundation of the business, with a focus on retaining the clients we serve and developing a path to generating durable, profitable revenue.”
Get started
Create a free account to read the full story.